Modulation of β-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors

European Journal of Pharmacology

Volumn 393, Issue 1-3, 2000, Pages 255-263

  Hellström Lindahl, Ewa ^a  

^a Occup Ther Elderly Care Res D ^*  (Sweden)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Amyloid peptide; Cholinesterase inhibitor; Muscarinic receptor; Nicotine; Nicotinic receptor; Plaque; Tangle; Tau

Indexed keywords

AF150S; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CALCIMYCIN; CARBACHOL; CEVIMELINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; EPIBATIDINE; GALANTAMINE; GLUTAMIC ACID; MUSCARINIC RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE; TACRINE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CONFERENCE PAPER; HUMAN; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; HUMANS; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; NICOTINE; NICOTINIC AGONISTS; PHOSPHORYLATION; RECEPTORS, CHOLINERGIC; RECEPTORS, MUSCARINIC; SMOKING; TAU PROTEINS;

EID: 0343570105     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00028-5     Document Type: Conference Paper

References (92)

1. Abe E., Casamenti F., Giovannelli L., Scali C., Pepeu G. Administration of amyloid beta-peptides into the medial septum of rats decreases acetylcholine release from hippocampus in vivo. Brain Res. 636:1994;162-164.
2. Akaike A., Tamura Y., Yokota T., Shimohama S., Kimura J. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644:1994;181-187.
3. Arendt T., Holzer M., Gertz H.-J., Brückner M.K. Cortical load of PHF-tau in Alzheimer's disease is correlated to cholinergic dysfunction. J. Neural. Trans. 106:1999;513-523.
4. Auld D.S., Kar S., Quirion R. β-Amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci. 21:1998;43-49.
5. 3H] nicotine binding sites in human brain. J. Neurochem. 50:1988;1242-1247.
6. Billingsley M.L., Kincaid R.L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem. J. 323:1997;577-591.
7. Busciglio J., Lorenzo A., Yeh J., Yankner B. β-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 14:1995;879-888.
8. Buxbaum J.D., Oishi M., Chen H.I., Pinkas-Kramarski R., Jaffe E.A., Gandy S.E., Greengard P. Cholinergic agonists and interleukin-1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA. 89:1992;10075-10078.
9. Buxbaum J.D., Koo E.H., Greengard P. Protein phosphorylation inhibits production of Alzheimer amyloid β/A4 peptide. Proc. Natl. Acad. Sci. USA. 90:1993;9195-9198.
10. Buxbaum J.D., Ruefli A.A., Parker C.A., Cypress A.A., Greengard P. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc. Natl. Acad. Sci. USA. 91:1994;4489-4493.
11. Checler F. Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease. J. Neurochem. 65:1995;1431-1444.
12. Cook D.G., Forman M.S., Sung J.C., Leight S., Kolson D.L., Iwatsubo T., Lee V.M.L., Doms R.W. Alzheimer's Aβ (1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat. Med. 3:1997;1021-1023.
13. Court J.A., Lloyd S., Thomas N., Piggott M.A., Marshall E.F., Morris C.M., Lamb H., Perry R.H., Johnson M., Perry E.K. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience. 87:1998;63-78.
14. Dyrks T., Mönning U., Beyreuther K., Turner J. Amyloid precursor protein secretion and βA4 amyloid generation are not mutually exclusive. FEBS Lett. 349:1994;210-214.
15. Efthimiopoulos S., Vassilacopoulou D., Ripellino J., Tezapsidis N., Robakis N.K. Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Proc. Natl. Acad. Sci. USA. 93:1996;8046-8050.
16. Fisher A., Brandeis R., Chapman S., Pittel Z., Michaelson D.M. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairment of apolipoprotein E-deficient mice. J. Neurochem. 70:1998;1991-1997.
17. Gandy S., Greengard P. Regulated cleavage of the Alzheimer amyloid precursor protein: molecular and cellular basis. Biochimie. 76:1994;300-303.
18. 1 muscarinic agonist treatment. J. Neurochem. 72:1999;206-213.
19. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M., Yankner B.A. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat. Med. 4:1998;827-831.
20. Giovannelli L., Casamenti F., Scali L., Bartolini L., Pepeu G. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis. Neuroscience. 66:1995;781-792.
21. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41:1997;17-24.
22. Greenberg S.M., Koo E.H., Selkoe D.J., Qui W.Q., Kosik K.S. Secreted β-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc. Natl. Acad. Sci. USA. 91:1994;7104-7108.
23. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., Selkoe D.J. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 359:1992;322-325.
24. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:1997;154-159.
25. Hartmann T., Bieger S.C., Bruhl B., Tienari P.J., Ida N., Allsop D., Roberts G.W., Masters C.L., Dotti C.G., Unsicker K., Beyreuther K. Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides. Nat. Med. 3:1997;1016-1020.
26. Hellström-Lindahl E., Moore H., Nordberg A. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J. Neurochem. 74:2000;. in press.
27. Holladay M., Dart M., Lynch J.K. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 40:1997;4169-4194.
28. 1-42 suppresses acetylcholine synthesis. J. Biol. Chem. 272:1997;2038-2041.
29. Hung A.Y., Haass C., Nitsch R.M., Qui W.Q., Citron M., Wurtman R.J., Growdon J.H., Selkoe D. Activation of protein kinase C inhibits cellular production of the amyloid β-protein. J. Biol. Chem. 268:1993;22959-22962.
30. Itoh A., Nitta A., Nadai M., Nishimura K., Hirose M., Hasegawa T., Nabeshima T. Dysfunction of cholinergic and dopaminergic neuronal system in beta-amyloid protein-infused rats. J. Neurochem. 66:1996;1113-1117.
31. Johnson G.V.W., Hartigan J.A. Tau protein in normal and Alzheimer's disease brain: an update. Alzheimer's Dis. Rev. 3:1998;125-141.
32. Kar S., Seto D., Gaudreau P., Quirion R. β-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J. Neurosci. 16:1996;1034-1040.
33. Kar S., Issa M., Seto D., Auld D.S., Collier B., Quirion R. Amyloid β-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J. Neurochem. 70:1998;2179-2187.
34. Kelly J.F., Furukawa K., Barger S.W., Rengen M.R., Mark R.J., Blanc E.M., Roth G.S., Mattson M.P. Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc. Natl. Acad. Sci. USA. 93:1996;6753-6758.
35. Kihara T., Shimohama S., Urushitani M., Sawada H., Kimura J., Kume T., Maeda T., Akaike A. Stimulation of α4β2 nicotinic acetylcholine receptors inhibits β-amyloid toxicity. Brain Res. 792:1998;331-334.
36. Kihara T., Shimohama S., Akaike A. Effects of nicotinic receptor agonists on beta-amyloid beta-sheet formation. Jpn. J. Pharmacol. 79:1999;393-396.
37. Kim S.-H., Kim Y.-K., Jeong S.-J., Haas C., Kim Y.-H., Suh Y.-H. Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. Mol. Pharmacol. 52:1997;430-436.
38. Kuisak J.W., Northon D.D., Sisodia S.S., Zhao B. The regulation of amyloid precursor protein processing by nicotinic cholinergic mechanisms. Soc. Neurosci. Abstr. 25:1999;598.
39. Ladner C.J., Lee J.M. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothes is revisited. J. Neuropathol. Exp. Neurol. 57:1998;719-731.
40. Lahiri D.K., Lewis S., Farlow M. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J. Neurosci. 37:1994;777-787.
41. Lahiri D.K., Farlow M., Sambamurti K. The secretion of amyloid β-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Mol. Brain Res. 62:1998;131-140.
42. Le W., Xie W.J., Kong R., Appel S. β-amyloid-induced neurotoxicity of a hybrid septal cell line associated with increased tau phosphorylation and expression of β-amyloid precursor protein. J. Neurochem. 69:1997;978-985.
43. Lee P.N. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology. 13:1994;13-144.
44. Li Y., Papke R.L., He Y.-J., Millard W.J., Meyer E.M. Characterization of the neuroprotective and toxic effects of α7 nicotinic receptor activation in PC12 cells. Brain Res. 830:1999;218-225.
45. Loeffler J., Huber G. Modulation of β-amyloid precursor protein secretion in differentiated and nondifferentiated cells. Biochem. Biophys. Res. Commun. 195:1993;97-103.
46. Maelicke A., Schrattenholz A., Storch A., Schröder B., Gutbrod O., Methfessel C., Weber K.-H., Pereira E., Alkondon M., Albuquerque E.X. Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction. J. Recept. Signal Transduction Res. 15:1995;333-353.
47. 2+ influx in cultured hippocampal neurons. Neuron. 2:1990;105-117.
48. Mattson M.P. Cellular aspects of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77:1997;1081-1132.
49. Merchant C., Tang M.-X., Albert S., Manly J., Stern Y., Mayeux R. The influence of smoking on the risk of Alzheimer's disease. Neurology. 52:1999;1408-1412.
50. Mills J., Reiner P.B. Regulation of amyloid precursor protein cleavage. J. Neurochem. 72:1999;443-460.
51. Mori F., Lai C.-C., Fusi F., Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. NeuroReport. 6:1995;633-636.
52. Newhouse P., Potter A., Levin E. Nicotinic system involvement in Alzheimer's and Parkinson's diseases, implications for therapeutics. Drugs Aging. 11:1997;206-228.
53. Nitsch R.M., Growdon J.H. Role of neurotransmission in the regulation of amyloid β-protein precursor processing. Biochem. Pharmacol. 47:1994;1275-1284.
54. Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptor. Science. 258:1992;304-307.
55. Nitsch R.M., Farber S.A., Growdon J.H., Wurtman R. Release of amyloid β-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc. Natl. Acad. Sci. USA. 90:1993;5191-5193.
56. Nitsch R.M., Deng M., Growdon J.H., Wurtman R. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J. Biol. Chem. 271:1996;4188-4194.
57. Nitsch R.M., Kim C., Growdon J.H. Vasopressin and bradykinin regulate secretory processing of the amyloid protein precursor of Alzheimer's disease. Neurochem. Res. 23:1998;807-814.
58. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 4:1992;303-328.
59. Nordberg A., Svensson A.-L. Cholinesterase inhibitors in the treatment of Alzheimer's disease. A comparison of tolerability and pharmacology. Drug Safety. 19:1998;465-480.
60. Nordberg A., Lilja A., Lundqvist H., Hartwig P., Amberla K., Viitanen M., Warpman U., Johansson M., Hellström-Lindahl E., Bjurling P., Fasth K.-J., Långström B., Winblad B. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol. Aging. 13:1992;747-758.
61. Ott A., Slooter A.J.C., Hofman A., van Harskamp F., Witteman J.C.M., Van Broeckhoven C., van Dijn C.M. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam study. Lancet. 351:1998;1840-1843.
62. Pavia J., de Ceballos M.L., Sanchez de la Cuesta F. Alzheimer's disease: relationship between muscarinic cholinergic receptors, β-amyloid and tau proteins. Fundam. Clin. Pharmacol. 12:1998;473-481.
63. Pedersen W.A., Kloczewiak M.A., Blusztajn J.K. Amyloid β-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci. USA. 93:1996;8068-8071.
64. Pereira E.F.R., Alkondon M., Reinhardt S., Maelicke A., Peng X., Lindstrom J., Whiting J., Albuquerque E.X. Physostigmine and galanthamine characterize the presence of a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J. Pharmacol. Exp. Ther. 270:1994;768-778.
65. Perry D.C., Davila-Garcia M.I., Stockmeier C.A., Kellar K. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther. 289:1999;1545-1552.
66. Perry E.K., Martin Ruiz C., Lee M., Griffiths M., Johnson M., Piggott M., Haroutunia H., Davis K., Gotti C., Tzartos R., Cohen O., Soreq H., Jaros E., Perry R., Ballard C., McKeith I., Court J. Nicotinic receptor subtypes in human brain aging, Alzheimer and Levy body diseases. Eur. J. Pharmacol. 1:2000;. (this Proceedings).
67. Pittel Z., Heldman E., Barg J., Haring R., Fisher A. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res. 742:1996;299-304.
68. Querfurth H.W., Selkoe D.J. Calcium ionophore increases amyloid β-peptide production by cultured cells. Biochemistry. 33:1994;4550-4561.
69. Sabbagh M., Galsko D., Thal J. β-amyloid and treatment opportunities for Alzheimer's disease. Alzheimer's Dis. Rev. 3:1997;1-19.
70. Sadot E., Gurwitz D., Barg J., Behar L., Ginzburg I., Fisher A. Activation of m1 muscarinic acetylcholine receptor regulates τ phosphorylation in transfected PC12 cells. J. Neurochem. 66:1996;877-880.
71. Salomon A.R., Marcinowski K.J., Friedland R.P., Zagorski M.G. Nicotine inhibits amyloid formation by the β-peptide. Biochemistry. 35:1996;13568-13578.
72. Selkoe D.J. Amyloid β-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271:1996;18295-18298.
73. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;23-31.
74. Shea T.B., Spencer M.J., Beerman M.L., Cressman C.M., Nixon R.A. Calcium influx into human neuroblastoma cells induces ALZ-50 immunoreactivity: involvement of calpain-mediated hydrolysis of protein kinase C. J. Neurochem. 66:1996;1539-1549.
75. Shea T.B., Prabhakar S., Ekinci F. β-amyloid and ionophore A23187 evoke tau hyperphosphorylation by distinct intracellular pathways:differential involvement of the calpain/protein kinase C system. J. Neurosci. Res. 49:1997;759-768.
76. Shimohama S., Greenwald D.L., Shafron D.H., Akaika A., Maeda T., Kaneko S., Kimura J., Simpkins C.E., Day A.L., Meyer E.M. Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res. 779:1998;359-363.
77. Sigurdsson E.M., Hejna M.J., Magnusson D.J., Lee J.M., Lorens S.A. β-amyloid 25-35 (βA) induced tau-immunoreactivity following injections into the amygdala of rats in vivo. Soc. Neurosci. Abstr. 21:1995;1719.
78. Sindou P., Lesort M., Couratier P., Yardin C., Esclaire F., Hugon J. Glutamate increases tau phosphorylation in primary neuronal cultures from fetal rat cerebral cortex. Brain Res. 646:1994;124-128.
79. Slack B.E., Breu J., Petryniak M.A., Srivastava K., Wurtman R.J. Tyrosine phosphorylation-dependent stimulation of amyloid precursor protein secretion by the m3 muscarinic acetylcholine receptor. J. Biol. Chem. 270:1995;8337-8344.
80. Small D.H., McLean C.A. Alzheimer's disease and the amyloid β protein: what is the role of amyloid? J. Neurochem. 73:1999;443-449.
81. Smith M.A., Siedlak S.L., Richey P.L., Mulvihill P., Ghiso J., Frangione B., Tagliavini F., Giaccone G., Bugiani O., Praprotnik D., Kalaria R.N., Perry G. Tau protein directly interacts with the amyloid β-protein precursor: implication for Alzheimer's disease. Nat. Med. 1:1995;365-370.
82. Spillantini M.G., Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21:1997;428-433.
83. Svensson A.-L., Nordberg A. Tacrine interacts with an allosteric activator site on α4β2 nAChRs in M10 cells. NeuroReport. 7:1996;2201-2205.
84. Svensson A.-L., Nordberg A. Interaction of tacrine, galanthamine, NXX-066 and E2020 with neuronal α4β2 nicotinic receptors expressed in fibroblast cells. Iqbal K., Winblad B., Nishimura T., Taked M., Wisniewski H.M. Alzheimer's Disease: Biology, Diagnosis and Therapeutics. 1997;753-758 Wiley.
85. (25-35) in rat PC12 cells. NeuroReport. 9:1998;1519-1522.
86. Takashima A., Nogushi K., Michel G., Hoshi M., Ishiguro K., Imahori K. Exposure of rat hippocampal neurons to amyloid β-peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β Neurosci. Lett. 203:1996;33-36.
87. Terry R.D. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol. 55:1996;1023-1025.
88. Ulrich J., Johannson-Locher G., Seiler W.O., Stähelin H.B. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol. 94:1997;450-454.
89. Vincent I., Rosado M., Kim E., Davies P. Increased production of paired helical filament epitopes in a cell culture system reduces the turnover of τ J. Neurochem. 62:1994;715-723.
90. Wevers A., Monteggia L., Nowacki S., Bloch W., Schütz U., Linstrom J., Pereira E.F.R., Eisenberg H., Giacobini E., de Vos R.A.I., Jansen Steur E.N.H., Maelicke A., Albuquerque E.X., Schröder H. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur. J. Neurosci. 11:1999;2551-2565.
91. Wolf B.A., Wertkin A.M., Jolly Y.C., Yasuda R.P., Wolfe B.B., Konrad R.J., Manning D., Ravi S., Williamson J.R., Lee V.M.-Y. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid β-protein production in human NT2N cells. J. Biol. Chem. 270:1995;4916-4922.
92. (25-35) in hippocampal cultures. NeuroReport. 8:1997;513-517.